295 related articles for article (PubMed ID: 25359397)
21. MXRA5 Is a Novel Immune-Related Biomarker That Predicts Poor Prognosis in Glioma.
Sun JZ; Zhang JH; Li JB; Yuan F; Tong LQ; Wang XY; Chen LL; Fan XG; Zhang YM; Ren X; Zhang C; Yu SP; Yang XJ
Dis Markers; 2021; 2021():6680883. PubMed ID: 34211612
[TBL] [Abstract][Full Text] [Related]
22. Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas.
Zeng J; Zhang XK; Chen HD; Zhong ZH; Wu QL; Lin SX
Oncotarget; 2016 Feb; 7(8):8944-55. PubMed ID: 26771840
[TBL] [Abstract][Full Text] [Related]
23. Identification of Secreted Phosphoprotein 1 (SPP1) as a Prognostic Factor in Lower-Grade Gliomas.
Chen J; Hou C; Zheng Z; Lin H; Lv G; Zhou D
World Neurosurg; 2019 Oct; 130():e775-e785. PubMed ID: 31295606
[TBL] [Abstract][Full Text] [Related]
24. Upregulated Expression of CUX1 Correlates with Poor Prognosis in Glioma Patients: a Bioinformatic Analysis.
Wu X; Feng F; Yang C; Zhang M; Cheng Y; Zhao Y; Wang Y; Che F; Zhang J; Heng X
J Mol Neurosci; 2019 Dec; 69(4):527-537. PubMed ID: 31377983
[TBL] [Abstract][Full Text] [Related]
25. Expression and prognostic value of JAM-A in gliomas.
Rosager AM; Sørensen MD; Dahlrot RH; Boldt HB; Hansen S; Lathia JD; Kristensen BW
J Neurooncol; 2017 Oct; 135(1):107-117. PubMed ID: 28677106
[TBL] [Abstract][Full Text] [Related]
26. Insights into the clinical value of cyclin-dependent kinase 5 in glioma: a retrospective study.
Yushan R; Wenjie C; Suning H; Yiwu D; Tengfei Z; Madushi WM; Feifei L; Changwen Z; Xin W; Roodrajeetsing G; Zuyun L; Gang C
World J Surg Oncol; 2015 Jul; 13():223. PubMed ID: 26205145
[TBL] [Abstract][Full Text] [Related]
27. Nrf2 Expressions Correlate with WHO Grades in Gliomas and Meningiomas.
Tsai WC; Hueng DY; Lin CR; Yang TC; Gao HW
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27187376
[TBL] [Abstract][Full Text] [Related]
28. Tumor-derived hepatocyte growth factor is associated with poor prognosis of patients with glioma and influences the chemosensitivity of glioma cell line to cisplatin in vitro.
Guo YF; Wang XB; Tian XY; Li Y; Li B; Huang Q; Zhang M; Li Z
World J Surg Oncol; 2012 Jun; 10():128. PubMed ID: 22741575
[TBL] [Abstract][Full Text] [Related]
29. Collaborative overexpression of matrix metalloproteinase-1 and vascular endothelial growth factor-C predicts adverse prognosis in patients with gliomas.
Xu Y; Zhong Z; Yuan J; Zhang Z; Wei Q; Song W; Chen H
Cancer Epidemiol; 2013 Oct; 37(5):697-702. PubMed ID: 23870768
[TBL] [Abstract][Full Text] [Related]
30. DTX3L is upregulated in glioma and is associated with glioma progression.
Xu P; Tao X; Zhao C; Huang Q; Chang H; Ban N; Bei Y; Xia X; Shen C; Wang K; Xu L; Wu P; Ren J; Wang D
Int J Mol Med; 2017 Aug; 40(2):491-498. PubMed ID: 28627634
[TBL] [Abstract][Full Text] [Related]
31. Expression and Prognostic Role of PANK1 in Glioma.
Zhao Z; Xu X; Ma S; Li L
Comb Chem High Throughput Screen; 2024; 27(5):715-724. PubMed ID: 37138430
[TBL] [Abstract][Full Text] [Related]
32. P4HB and PDIA3 are associated with tumor progression and therapeutic outcome of diffuse gliomas.
Zou H; Wen C; Peng Z; Shao YΥ; Hu L; Li S; Li C; Zhou HH
Oncol Rep; 2018 Feb; 39(2):501-510. PubMed ID: 29207176
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of kappaB-Ras1 expression in gliomas.
Lin H; Wang Y; Zhang X; Liu B; Zhang W; Cheng J
Med Oncol; 2012 Jun; 29(2):1272-9. PubMed ID: 21302000
[TBL] [Abstract][Full Text] [Related]
34. miR-320a functions as a suppressor for gliomas by targeting SND1 and β-catenin, and predicts the prognosis of patients.
Li H; Yu L; Liu J; Bian X; Shi C; Sun C; Zhou X; Wen Y; Hua D; Zhao S; Ren L; An T; Luo W; Wang Q; Yu S
Oncotarget; 2017 Mar; 8(12):19723-19737. PubMed ID: 28160566
[TBL] [Abstract][Full Text] [Related]
35. Expression and prognostic value of the WEE1 kinase in gliomas.
Music D; Dahlrot RH; Hermansen SK; Hjelmborg J; de Stricker K; Hansen S; Kristensen BW
J Neurooncol; 2016 Apr; 127(2):381-9. PubMed ID: 26738845
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of stem cell marker CD133 determined by promoter methylation but not by immunohistochemical expression in malignant gliomas.
Wu X; Wu F; Xu D; Zhang T
J Neurooncol; 2016 Apr; 127(2):221-32. PubMed ID: 26757925
[TBL] [Abstract][Full Text] [Related]
37. Oncogenic role of SOX9 expression in human malignant glioma.
Wang L; He S; Yuan J; Mao X; Cao Y; Zong J; Tu Y; Zhang Y
Med Oncol; 2012 Dec; 29(5):3484-90. PubMed ID: 22714060
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of ubiquitin-specific protease 2a (USP2a) and nuclear factor erythroid 2-related factor 2 (Nrf2) in human gliomas.
Boustani MR; Khoshnood RJ; Nikpasand F; Taleshi Z; Ahmadi K; Yahaghi E; Goudarzi PK
J Neurol Sci; 2016 Apr; 363():249-52. PubMed ID: 27000259
[TBL] [Abstract][Full Text] [Related]
39. Identification of PIEZO1 as a potential prognostic marker in gliomas.
Zhou W; Liu X; van Wijnbergen JWM; Yuan L; Liu Y; Zhang C; Jia W
Sci Rep; 2020 Sep; 10(1):16121. PubMed ID: 32999349
[TBL] [Abstract][Full Text] [Related]
40. [CDK1 expression and effects of CDK1 silencing on the malignant phenotype of glioma cells].
Chen H; Huang Q; Zhai DZ; Dong J; Wang AD; Lan Q
Zhonghua Zhong Liu Za Zhi; 2007 Jul; 29(7):484-8. PubMed ID: 18069625
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
